Evolocumab
- Generic Name
- Evolocumab
- Brand Names
- Repatha
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1256937-27-5
- Unique Ingredient Identifier
- LKC0U3A8NJ
- Background
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies....
- Indication
Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with hete...
- Associated Conditions
- Coronary Revascularization, Myocardial Infarction, Stroke, Increases in serum total low-density lipoprotein (LDL)
- Associated Therapies
- -
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Robert Rosenson
- Target Recruit Count
- 41
- Registration Number
- NCT03829046
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇨🇦St. Michael's - University of Toronto, Toronto, Ontario, Canada
EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Fundació Institut Germans Trias i Pujol
- Target Recruit Count
- 46
- Registration Number
- NCT03791593
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital Clínico de Valencia, Valencia, Spain
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Lars Gullestad
- Target Recruit Count
- 130
- Registration Number
- NCT03734211
- Locations
- 🇩🇰
Department of Cardiology, Aarhus University Hospital, Skejby, Denmark
🇫🇮Helsinki University Hospital Heart and Lung Center, Helsinki, Finland
🇩🇰Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
Effect of Evolocumab on Coronary Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT03689946
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Imaging of Coronary Plaques in Participants Treated With Evolocumab
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 164
- Registration Number
- NCT03570697
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇭🇺Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
Evolocumab in Acute Coronary Syndrome
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 60
- Registration Number
- NCT03515304
- Locations
- 🇺🇸
Steven Paul Schulman, Baltimore, Maryland, United States
Effect of Evolocumab on Coronary Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 19
- Registration Number
- NCT03500302
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 259
- Registration Number
- NCT03433755
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Hospital General Universitario Gregorio Marañon
- Target Recruit Count
- 9
- Registration Number
- NCT03429998
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain
Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT03403374
- Locations
- 🇮🇳
Research Site, Lucknow, Uttar Pradesh, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.